Stockreport

Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF France, March 16, 2019 (GLOBE NEWSWIRE) -- Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with establish [Read more]